Lysosomal storage disorders (LSDs) comprise a class of inherited diseases characterized by disruption of normal lysosomal function and the consequent accumulation of incompletely degraded substrates. Most LSDs are caused by loss of function of specific lysosomal acid hydrolases, which act to degrade complex substrates that have been targeted for degradation after endocytosis or autophagy. The degradation occurs by a stepwise pathway, and if one step in the process fails, further degradation often ceases and the partially degraded substrate accumulates. The ensuing substrate accumulation in lysosomes affects the architecture and function of cells, tissues, and organs. In some cases, the accumulated substrate itself (as in Galactocerebrosidosis) or the product of an alternative metabolic route, which is upregulated by the accumulated primary substrate (as in the case of psycosine in Globoid Cell Leukodystrophy), is cytotoxic and leads to cell dysfunction or death. In other cases, the actual molecular mechanism triggered by the accumulated metabolite and leading to cellular toxicity and tissue pathology remains elusive.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ailles L., Schmidt M., Santoni de Sio F.R., Glimm H., Cavalieri S., Bruno S., Piacibello W., Von Kalle C., and Naldini L. (2002). Molecular evidence of lentiviral vectormediated gene transfer into human self-renewing, multi-potent, long-term NOD/ SCID repopulating hematopoietic cell. Mol. Ther. 6, 615-626.
Asheuer M., Pflumio F., Benhamida S., Dubart-Kupperschmitt A., Fouquet F., Imai Y., Aubourg P., and Cartier N. (2004). Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc. Natl. Acad. Sci. U.S.A. 101(10), 3557-3562.
Baekelandt V., Claeys A., Eggermont K., Lauwers E., De Strooper B., Nuttin B., and Debyser Z. (2002). Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum. Gene Ther. 13, 841-853.
Barranger J.A. and O’Rourke E. (2001). Lessons learned from the development of enzyme therapy for Gaucher disease. J. Inherit. Metab. Dis. 24 Suppl 2, 89-96.
Barsoum S.C., Milgram W., Mackay W., Coblentz C., Delaney K.H., Kwiecien J.M., Kruth S.A., and Chang P.L. (2003). Delivery of recombinant gene product to canine brain with the use of microencapsulation. J. Lab. Clin. Med. 142(6), 399-413.
Biffi A., De Palma M., Quattrini A., Del Carro U., Amadio S., Visigalli I., Sessa M., Fasano S., Brambilla R., Marchesini S., Bordignon C., and Naldini L. (2004). Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest. 113(8), 1118-1129.
Birkenmeier E.H., Davisson M.T., Beamer W.G., Ganschow R.E., Vogler C.A., Gwynn B., Lyford K.A., Maltais L.M., and Wawrzyniak C.J. (1989). Murine mucopolysacc-haridosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J. Clin. Invest. 83(4), 1258-1266.
Blakemore W.F., Gilson J.M., and Crang A.J. (2003). The presence of astrocytes in areas of demyelination influences remyelination following transplantation of oligoden-drocyte progenitors. Exp. Neurol. 184(2), 955-963.
Blomer U., Naldini L., Kafri T., Trono D., Verma I.M., and Gage F.H. (1997). Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71 (9), 6641-6649.
Bosch A., Perret E., Desmaris N., Trono D., and Heard J.M. (2000). Reversal of patho-logy in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. 11, 1139-1150.
Brooks A.I., Stein C.S., Hughes S.M., Heth J., McCray P.M., Sauter S.L., Johnston J.C., Selechta D.A., Federoff H.J., and Davidson B.L. (2002). Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. 99, 6216-6221.
Buchet D., Serguera C., Zennou V., Charneau P., and Mallet J. (2002). Long-term expression of beta-glucuronidase by genetically modified human neural progenitor cells grafted into the mouse central nervous system. Mol. Cell. Neurosci. 19(3), 389-401.
Chao H. and Walsh C.E. (2001). Induction of tolerance to human factor VII in mice. Blood 97, 3311-3312.
Consiglio A., Gritti A., Dolcetta D., Follenzi A., Bordignon C., Gage F.H., Vescovi A.L., and Naldini L. (2004). Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. Proc. Natl. Acad. Sci. U.S.A. 101(41), 14835-14840.
Consiglio A., Quattrini A., Martino S., Bensadoun J.C., Dolcetta D., Trojani A., Benaglia G., Marchesini S., Cestari V., Oliverio A., Bordignon C., and Naldini L. (2001). In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: Correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. 7, 310-316.
Cosma M.P., Pepe S., Annunziata I., Newbold R.F., Grompe M., Parenti G., and Ballabio A. (2003). The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 113(4), 445-456.
Daly T.M. (2004). AAV-mediated gene transfer to the liver. Methods Mol. Biol. 246, 195-199.
Daly T.M., Lorenz R., and Sands M.S. (2000). Abnormal immune function in vivo in a murine model of lysosomal storage disease. Pediatr. Res. 47, 757-762.
De Palma M., Montini E., Santoni de Sio F.R., Benedicenti F., Gentile A., Medico E., and Naldini L. (2004). Promoter trapping reveals significant differences in integra-tion site selection between MLV and HIV vectors in primary hematopoietic cells. Blood, 105(6), 2307-2315.
Desmaris N., Verot L., Puech J.P., Caillaud C., Vanier M.T., and Heardt J.M. (2004). Prevention of neuropathology in the mouse model of Hurler syndrome. Ann. Neurol. 56, 68-76.
Desnick R.J., Ioannou Y.A., and Eng C.M. (2001). Metabolic and Molecular Bases of Inherited Diseases. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. (Eds.) (New York: McGraw-Hill) pp. 3733-3774.
Di Domenico C., Villani G.R., Di Napoli D., Reyero E.G., Lombardo A., Naldini L., and Di Natale P. (2005). Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum Gene Ther. 16(1), 81-90.
Eglitis M.A. and Mezey E. (1997). Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc. Natl. Acad. Sci. U.S.A. 94, 4080-4085.
Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., and Desnick R.J. (2001). Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s disease. N. Engl. J. Med. 345, 9-16.
Englund U., Bjorklund A., and Wictorin K. (2002). Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after trans-plantation into the adult rat brain. Brain Res. Dev. Brain Res. 134(1-2), 123-141.
Espinosa de los Monteros A., Baba H., Zhao P.M., Pan T., Chang R., de Vellis J., and Ikenaka K. (2001). Remyelination of the adult demyelinated mouse brain by grafted oligodendrocyte progenitors and the effect of B-104 cografts. Neurochem. Res. 26 (6), 673-682.
Fischer A., Abina S.H., Thrasher A., von Kalle C., and Cavazzana-Calvo M. (2004). LMO2 and gene therapy for severe combined immunodeficiency. N. Engl. J. Med. 350, 2526-2527.
Flax J.D., Aurora S., Yang C., Simonin C., Wills A.M., Billinghurst L.L., Jendoubi M., Sidman R.L., Wolfe J.H., Kim S.U., and Snyder E.Y. (1998). Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat. Biotechnol. 16(11), 1033-1039.
Follenzi A. and Naldini L. (2002a). HIV-based vectors. Preparation and use. Methods Mol. Med. 69, 259-274.
Follenzi A. and Naldini L. (2002b). Generation of HIV-1 derived lentiviral vectors. Methods Enzymol. 346, 454-465.
Follenzi A., Battaglia M., Lombardo A., Annoni A., Roncarolo M.G., and Naldini L. (2004). Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 103(10), 3700-3709.
Follenzi A., Sabatino G., Lombardo A., Boccaccio C., and Naldini L. (2002). Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13(2), 243-260.
Fricker R.A., Carpenter M.K., Winkler C., Greco C., Gates M.A., and Bjorklund A. (1999). Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J. Neurosci. 19(14), 5990-6005.
Gage F.H., Ray J., and Fisher L.J. (1995). Isolation, characterization, and use of stem cells from the CNS. Annu. Rev. Neurosci. 18, 159-192.
Gao C., Sands M.S., Haskins M.E., and Parker Ponder K. (2000). Delivery of retroviral vector expressing human beta-glucuronidase to the liver and spleen decreases lyso-somal storage in mucopolysaccharidosis VII mice. Mol. Ther. 2, 233-244.
Georgievska B., Kirik D., Rosenblad C., Lundberg C., and Bjorklund A. (2002). Neuro-protection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13, 75-82.
German D.C., Liang C.L., Song T., Yazdani U., Xie C., and Dietschy J.M. (2002). Neurode-generation in the Niemann-Pick C mouse: Glial involvement. Neuroscience 109(3), 437-450.
Glorioso J.C., Mata M., and Fink D.J. (2003). Therapeutic gene transfer to the nervous system using viral vectors. J. Neurovirol. 9, 165-172.
Griffey M., Bible E., Vogler C., Levy B., Gupta P., Cooper J., and Sands M. (2004). Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantiole neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16(2), 360-369.
Guenechea G., Gan O.I., Dorrell C., and Dick J.E. (2001). Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat. Immunol. 2, 75-82.
Hartung S.D., Frandsen J.L., Pan D., Koniar B.L., Graupman P., Gunther R., Low W.C., Whitley C.B., and McIvor R.S. (2004). Correction of metabolic, craniofacial, and neurologic abnormalities in MPSI mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol. Ther. 9(6), 866-875.
Haskell R.E., Hughes S.M., Chiorini J.A., Alisky J.M., and Davidson B.L. (2003). Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system. Gene Ther. 10(1), 34-42.
Hess B., Saftig P., Hartmann D., Coenen R., Lullmann-Rauch R., Goebel H.H., Evers M., von Figura K., D’Hooge R., Nagels G., De Deyn P., Peters C., and Gieselmann V. (1996). Phenotype of arylsulfatase A-deficient mice: Relationships to human metachromatic leukodystrophy. Proc. Natl. Acad. Sci. U.S.A. 93, 14821-14826.
Hofling A.A., Devine S., Vogler C., and Sands M.S. (2004). Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. Mol. Ther. 9(6), 856-865.
Kakkis E., Lester T., Yang R., Tanaka C., Anand V., Lemontt J., Peinovich M., and Passage M. (2004). Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. Proc. Natl. Acad. Sci. U.S.A. 101(3), 829-834.
Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., and Neufeld E.F. (2001). Enzyme-replace-ment therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344, 182-188.
Kay M.A., Glorioso J.C., and Naldini L. (2001). Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7, 33-40.
Kennedy D.W. and Abkowitz J.L. (1997). Kinetics of central nervous system microglial and macrophage engraftment. Analysis using a transgenic bone marrow transplant-tation model. Blood 90, 986-993.
Kim J.H., Auerbach J.M., Rodriguez-Gomez J.A., Velasco I., Gavin D., Lumelsky N., Lee S.H., Nguyen J., Sanchez-Pernaute R., Bankiewicz K., and McKay R. (2002). Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nature 418, 50-56.
Kordower J.H., Bloch J., Ma S.Y., Chu Y., Palfi S., Roitberg B.Z., Emborg M., Hantraye P., Deglon N., and Aebischer P. (1999). Lentiviral gene transfer to the nonhuman primate brain. Exp. Neurol. 160, 1-16.
Kosuga M., Takahashi S., Tanabe A., Fujino M., Li X.K., Suzuki S., Yamada M., Kakishita K., Ono F., Sakuragawa N., and Okuyama T. (2001). Widespread distribu-tion of adenovirus-transduced monkey amniotic epithelial cells after local intracerebral injection: Implication for cell-mediated therapy for lysosome storage disorders. Cell Transplant. 10(4-5), 435-439.
Krivit W., Aubourg P., Shapiro E., and Peters C. (1999). Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr. Opin. Hematol. 6, 377-382.
Krouwer H.G. and Wijdicks E.F. (2003). Neurologic complications of bone marrow transplantation. Neurol. Clin. 21(1), 319-352.
Leiming T., Mann L., del Pilar Martin M., Bonten E., Persons D., Knowles J., Allay J.A., Cunningham J., Nienhuis A.W., Smeyne R., and d’Azzo A. (2002). Functional amelio-ration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells. Blood 99(9), 3169-3178.
Luca T., Givogri M.I., Perani L., Galbiati F., Follenzi A., Naldini L., and Bongarzone E.R. (2005). Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery. Mol. Ther. 12(4), 669-679.
Mango R.L., Xu L., Sands M.S., Vogler C., Seiler G., Schwarz T., Haskins M.E., and Parker Ponder K. (2004). Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs, Mol. Genetics and Metab. 82, 4-19.
Matzner U., Harzer K., Learish R.D., Barranger J.A., and Gieselmann V. (2000). Long-term expression and transfer of arylsulfatase A into brain of arylsulfatase A-deficient mice transplanted with bone marrow expressing the arylsulfatase A cDNA from a retroviral vector. Gene Ther. 7, 1250-1257.
Matzner U., Schestag F., Hartmann D., Lullmann-Rauch R., D’Hooge R., De Deyn P.P., and Gieselmann V. (2001). Bone marrow stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type cells. Hum. Gene Ther. 12, 1021-1033.
McCormack J.E., Edwards W., Sensintaffer J., Lillegren L., Kozloski M., Brumm D., Karavodin L., Jolly D.J., and Greengard J. (2001). Factors affecting long-term expre-ssion of a secreted transgene product after intravenous administration of a retroviral vector. Mol. Ther. 3(4), 516-525.
McKay R. (1997). Stem cells in the central nervous system. Science 276(5309), 66-71.
Meng X.L., Shen J.S., Ohashi T., Maeda H., Kim S.U., and Eto Y. (2003). Brain transplan-tation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. J. Neurosi. Res. 74(2), 266-277.
Mezey E., Key S., Vogelsang G., Szalayova I., Lange G.D., and Crain B. (2003). Trans-planted bone marrow generates new neurons in human brains. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1364-1369.
Mingozzi F., Liu Y.L., Dobrzynski E., Kaufhold A., Liu J.H., Wang Y., Arruda V.R., High K.A., and Herzog R.W. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest. 111, 1347-1356.
Miyoshi H., Blomer U., Takahashi M., Gage F.H., and Verma I.M. (1998). Development of a self-inactivating lentivirus vector. J. Virol. 72(10), 8150-8157.
Miyoshi H., Smith K.A., Mosier D.E., Verma I.M., and Torbett B.E. (1999). Trans-duction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283, 682-686.
Mount J.D., Herzog R.W., Tillson D.M., Goodman S.A., Robinson N., McCleland M.L., Bellinger D., Nichols T.C., Arruda V.R., Lothrop C.D. Jr., and High K.A. (2002). Sustained phenotypic correction of hemophilia B dogs with factor IX null mutation by liver-directed gene therapy. Blood 99, 2670-2676.
Naldini L. (1998). Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol. 9(5), 457-463.
Naldini L., Blomer U., Gage F.H., Trono D., and Verma I.M. (1996). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 93, 11382-11388.
Neufeld E.F. (1991). Lysosomal disease. Annu. Rev. Biochem. 60, 257-280.
Nguyen T.H., Oberholzer J., Birraux J., Majno P., Morel P., and Trono D. (2002). Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol. Ther. 6(2), 199-209.
Ohmi K., Greenberg D.S., Rajavel K.S., Ryazantsev S., Li H.H., and Neufeld E.F. (2003). Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. U.S.A. 100, 1902-1907.
Ourednik V., Ourednik J., Flax J.D., Zawada W.M., Hutt C., Yang C., Park K.I., Kim S.U., Sidman R.L., Freed C.R., and Snyder E.Y. (2001). Segregation of human neural stem cells in the developing primate forebrain. Science 293(5536), 1820-1824.
Parker Ponder K., Melniczek J.R., Xu L., Weil M.A., O’Malley T.M., O’Donnel P.A., Knox V.W., Aguirre G.D., Mazrier H., Ellinwood N.M., Sleeper M., Maguire A.M., Volk S.W., Mango R.L., Zweigle J., Wolfe J.H., and Haskins M.E. (2002). Therapeutical neonatal hepatic gene therapy in mucopolisaccharidosis VII dogs. Proc. Natl. Acad. Sci. U.S.A. 99(20), 13102-13107.
Peters C. and Steward C.G. (2003). Hematopoietic cell transplantation for inherited metabolic diseases: An overview of outcomes and practice guidelines. Bone Marrow Transplant. 31, 229-239.
Pluchino S., Quattrini A., Brambilla E., Gritti A., Salani G., Dina G., Galli R., Del Carro U., Amadio S., Bergami A., Furlan R., Comi G., Vescovi A.L., and Martino G. (2003). Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422(6933), 688-694.
Priller J., Flugel A., Wehner T., Boentert M., Haas C.A., Prinz M., Fernandez-Klett F., Prass K., Bechmann I., de Boer B.A., Frotscher M., Kreutzberg G.W., Persons D.A., and Dirnagl U. (2001). Targeting gene-modified hematopoietic cells to the central nervous system: Use of green fluorescent protein uncovers microglial engraftment. Nat. Med. 7, 1356-1361.
Reddy P.S., Sakhuja K., Ganesh S., Yang L., Kayda D., Brann T., Pattison S., Golightly D., Idamakanti N., Pinkstaff A., Kaloss M., Barjot C., Chamberlain J.S., Kaleko M., and Connelly S. (2002). Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol. Ther. 5(1), 63-73.
Ross C.J., Ralph M., and Chang P.L. (2000). Somatic gene therapy for a neurodegenera-tive disease using microencapsulated recombinant cells. Exp. Neurol. 166(2), 276-286.
Rubio F.J., Bueno C., Villa A., Navarro B., and Martinez-Serrano A. (2000). Genetically perpetuated human neural stem cells engraft and differentiate into the adult mammalian brain. Mol. Cell. Neurosci. 16(1), 1-13.
Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., and Brady R.O. (2001). Enzyme replacement therapy in Fabry disease: A randomized controlled trial. J. Am. Med. Assoc. 285, 2743-2749.
Schroder A., Shinn P., Chen H., Berry C., Ecker J., and Bushman F. (2002). HIV-1 inte-gration in the human genome favors active genes and local hotspots. Cell. 110, 521.
Sferra T.J., Backstrom K., Chuansong W., Rennard R., Miller M., and Hu Y. (2004). Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol. Ther. 10(3), 478-491.
Skorupa A.F., Fisher K.J., Wilson J.M., Parente M.K., and Wolfe J.H. (1999). Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp. Neurol. 160 (1), 17-27.
Sly W.S. (1993). Gene therapy on the Sly. Nat Genet. 4(2),105-106.
Sly W.S., Vogler C., Grubb J.H., Zhou M., Jiang J., Zhou X.Y., Tomatsu S., Bi Y., and Snella E.M. (2001). Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPSVII mice. Proc. Natl. Acad. Sci. U.S.A. 98, 3311-3312.
Snyder E.Y. (1995). Immortalized neural stem cells: insights into development; prospects for gene therapy and repair. Proc. Natl. Acad. Sci. U.S.A. 107(2), 195-204.
Solaro C., Nurialdo A., Giunti D., Mancardi G., and Uccelli A. (2001). Central and peripheral nervous system complications following allogeneic bone marrow trans-plantation. Europ. J. Neurol. 8, 77-80.
Stein C.S., Ghodsi A., Dersen T., and Davidson B.L. (1999). Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J. Virol. 73, 3424-3429.
Stein C.S., Kang Y., Sauter S.L., Townsend K., Staber P., Derksen T.A., Martins I., Qian J., Davidson B.L., and McCray P.B. Jr. (2001). In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol. Ther. 3 (6), 850-856.
Tamaki S., Eckert K., He D., Sutton R., Doshe M., Jain G., Tushinski R., Reitsma M., Harris B., Tsukamoto A., Gage F., Weissman I., and Uchida N. (2002). Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. J. Neurosci. Res. 69(6), 976-986.
Taylor R.M. and Wolfe J.H. (1997). Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nat. Med. 3(7), 771-774.
Unger, E.R., Sung J.H., Manivel J.C., Chenggis M.L., Blazar B.R., and Krivit W. (1993). Male donor-derived cells in the brains of female sex-mismatched bone marrow trans-plant recipients: a Y-chromosome specific in situ hybridization study. J. Neuropathol. Exp. Neurol. 52(5), 460-470.
Van den Hout J.M., Kamphoven J.H., Winkel L.P., Arts W.F., De Klerk J.B., Loonen M.C., Vulto A.G., Cromme-Dijkhuis A., Weisglas-Kuperus N., Hop W., Van Hirtum H., Van Diggelen O.P., Boer M., Kroos M.A., Van Doorn P.A., Van der Voort E., Sibbles B., Van Corven E.J., Brakenhof J.P., Van Hove J., Smeitink J.A., de Jong G., Reuser A.J., and Van der Ploeg A.T. (2004). Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113 (5), 448-457.
Wada R., Tifft C.J., and Proia R.L. (2000). Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl. Acad. Sci. U.S.A. 97(20), 10954-10959.
Walkley S.U., Thrall M.A., Dobreins K., Huang M., March P.A., Siegel D.A., and Wurzelmann S. (1994). Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc. Natl. Acad. Sci. U.S.A. 91, 2970-2974.
Watson G.L., Sayles J.N., Chen C., Elliger S.S., Elliger C.A., Raju N.R., Kurtzman G.J., and Podsakoff G.M. (1998). Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Ther. 5(12), 1642-1649.
Weimann J.M., Charlton C.A., Brazelton T.R., Hackman R.C., and Blau H.M. (2003). Contribution of transplanted bone marrow cells to Purkinje neurons in human adult brains. Proc. Natl. Acad. Sci. U.S.A. 100(4), 2088-2093.
Wichterle H., Lieberam I., Porter J.A., and Jessell T.M. (2002). Directed differentiation of embryonic stem cells into motor neurons. Cell 110, 385-397.
Wu P., Tarasenko Y.I., Gu Y., Huang L.Y., Coggeshall R.E., and Yu Y. (2002). Region-specific generation of cholinergic neurons from fetal human neural stem cells grafted in adult rat. Nat. Neurosci. 5(12), 1271-1278.
Wu X., Li Y., Crise B., and Burgess S.M. (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751.
Yeager A.M., Shinn C., Shinohara M., and Pardoll D.M. (1993). Hematopoietic cell transplantation in the twitcher mouse. The effects of pretransplant conditioning with graded doses of busulfan. Transplantation 56(1), 185-189.
Yeager A.M., Shinohara M., and Shinn C. (1991). Hematopoietic cell transplantation after administration of high-dose busulfan in murine globoid cell leukodystrophy (the twitcher mouse). Pediatr. Res. 29(3), 302-305.
Zheng Y., Rozengurt N., Ryazantsev S., Kohn D.B., Satyake N., and Neufeld E.F. (2003). Treatment of the mouse model of mucopolysaccharidosis I with retrovirally tyransduced bone marrow. Mol. Genetics and Metab. 79, 233-244.
Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., and Trono D. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 72(12), 9873-9880.
Zufferey R., Nagy D., Mandel R.J., Naldini L., and Trono D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15(9), 871-875.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Biffi, A., Naldini, L. (2007). Gene Therapy of Lysosomal Storage Disorders by Lentiviral Vectors. In: Lysosomal Storage Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-70909-3_10
Download citation
DOI: https://doi.org/10.1007/978-0-387-70909-3_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-70908-6
Online ISBN: 978-0-387-70909-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)